公开(公告)号：EP0963370B1

公开(公告)日：2003-03-19

申请号：EP97952325.5

申请日：1997-12-08

申请人： ELI LILLY AND COMPANY ,  Millennium Pharmaceuticals, Inc.

发明人： FISHER, Matthew, J. ,  FRANCISKOVICH, Jeffry, Bernard ,  JAKUBOWSKI, Joseph, A. ,  MASTERS, John, J. ,  SCARBOROUGH, Robert, M. ,  SMYTH, Mark ,  SU, Ting

IPC分类号： C07C311/00 ,  C07D211/04 ,  A61K31/18 ,  A61K31/445

CPC分类号： C07C311/06 ,  C07C311/19 ,  C07C2601/14 ,  C07D211/62

公开(公告)号：EP1322643A1

公开(公告)日：2003-07-02

申请号：EP01979304.1

申请日：2001-10-01

申请人： Millennium Pharmaceuticals, Inc.

发明人： ZHU, Bing-Yan ,  SU, Ting ,  LI, Wenhao ,  GOLDMAN, Erick, A. ,  ZHANG, Penglie ,  JIA, Zhaozhong, Jon ,  SCARBOROUGH, Robert, M.

IPC分类号： C07D409/12 ,  C07D409/14 ,  C07D241/08 ,  C07D403/10 ,  C07D401/14 ,  C07D491/113 ,  C07D401/12 ,  C07D405/14 ,  A61K31/495 ,  A61P7/02

CPC分类号： C07D401/10 ,  C07D241/08 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D491/10

摘要： Novel piperazin-2-one containing compounds of general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivative having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.

公开(公告)号：EP1235807A1

公开(公告)日：2002-09-04

申请号：EP00980439.4

申请日：2000-11-17

申请人： Millennium Pharmaceuticals, Inc.

发明人： ZHU, Bing-Yan ,  WANG, Lingyan ,  HUANG, Wenrong ,  WU, Yanhong ,  ZUCKETT, Jingmei, Fan ,  SU, Ting ,  SCARBOROUGH, Robert

IPC分类号： C07D213/75 ,  C07D295/18 ,  C07C311/16 ,  C07C311/18 ,  C07D409/12 ,  A61K31/44 ,  A61K31/18 ,  A61P7/02

CPC分类号： C07D213/81 ,  C07C311/16 ,  C07C311/19 ,  C07C311/46 ,  C07D295/185

摘要： Novel β-amino acid-, aspartic acid- and diaminopropionic-based compounds of the general formula A-Q-D-E-G-J-X wherein A, Q, D, E, G, J and X have the meanings given in the description, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.